metricas
covid
Buscar en
Hipertensión y Riesgo Vascular
Toda la web
Inicio Hipertensión y Riesgo Vascular Hipertensión maligna y feocromocitoma: reporte de un caso
Journal Information
Vol. 38. Issue 4.
Pages 201-205 (October - December 2021)
Share
Share
Download PDF
More article options
Visits
285
Vol. 38. Issue 4.
Pages 201-205 (October - December 2021)
Caso clínico
Hipertensión maligna y feocromocitoma: reporte de un caso
Malignant hypertension and pheochromocytoma: a case report
Visits
285
R. Burya,$, J. Leon Romana,$, A. Casterasb, A. Vergaraa, B. Biagettib, C. García-Carroa, E. Cordero-Vazquezb, I. Hernández Hernándezb, I. Agraza, M.J. Solera,
Corresponding author
m.soler@vhebron.net

Autor para correspondencia.
a Servicio de Nefrología, Hospital Universitario Vall d’Hebron, Barcelona, España
b Servicio de Endocrinología, Hospital Universitario Vall d’Hebron, Barcelona, España
This item has received
Article information
Abstract
Full Text
Bibliography
Download PDF
Statistics
Figures (3)
Show moreShow less
Tables (1)
Tabla 1. Evolución de resultados analíticos de la paciente con feocromocitoma y emergencia hipertensiva
Resumen

La hipertensión arterial maligna se define por cifras extremadamente altas de presión arterial asociadas a daño orgánico. Constituye una causa de emergencia hipertensiva donde coexisten cifras elevadas de presión arterial, con hemorragia y exudados bilaterales retinianas (retinopatía hipertensiva grado III), con o sin papiledema (retinopatía hipertensiva grado IV), asociada usualmente a lesión renal o cardíaca. En un 1% de los casos es secundaria a causas endocrinológicas, entre ellas, la más frecuente: el feocromocitoma, que clásicamente se ha caracterizado por la tríada cefalea, sudoración y palpitaciones. Sin embargo, no existe un hallazgo clínico único que tenga un valor significativo en su diagnóstico. A continuación, presentamos el caso de una paciente de 23 años con emergencia hipertensiva y masa suprarrenal asociado a retinopatía hipertensiva grado IV.

Palabras clave:
Hipertensión maligna
Feocromocitoma
Emergencia hipertensiva
Abstract

Malignant arterial hypertension is defined by extremely high levels of pressure associated with organ damage. It is a cause of hypertensive emergency and is defined by the coexistence of high blood pressure and bilateral retinal haemorrhage or exudates (grade III hypertensive retinopathy), with or without papilloedema (grade IV hypertensive retinopathy) currently associated with organ damage such as renal or cardiac failure. Around 1% of malignant arterial hypertension is secondary to endocrinological causes, including the most common: pheochromocytoma, which is classically characterized by the triad: headache, sweating and palpitations. However, there is no single clinical finding that is of significant value in its diagnosis. We now present the case of a 23-year-old patient with a hypertensive emergency, an adrenal mass associated with grade IV hypertensive retinopathy.

Keywords:
Malignant hypertension
Pheochromocytoma
Hypertensive emergency

Article

These are the options to access the full texts of the publication Hipertensión y Riesgo Vascular
Subscriber
Subscriber

If you already have your login data, please click here .

If you have forgotten your password you can you can recover it by clicking here and selecting the option “I have forgotten my password”
Subscribe
Subscribe to

Hipertensión y Riesgo Vascular

Purchase
Purchase article

Purchasing article the PDF version will be downloaded

Price 19.34 €

Purchase now
Contact
Phone for subscriptions and reporting of errors
From Monday to Friday from 9 a.m. to 6 p.m. (GMT + 1) except for the months of July and August which will be from 9 a.m. to 3 p.m.
Calls from Spain
932 415 960
Calls from outside Spain
+34 932 415 960
E-mail
Article options
es en pt

¿Es usted profesional sanitario apto para prescribir o dispensar medicamentos?

Are you a health professional able to prescribe or dispense drugs?

Você é um profissional de saúde habilitado a prescrever ou dispensar medicamentos

Quizás le interese:
10.1016/j.hipert.2024.04.001
No mostrar más